273P Experiences and preferences about information on treatment (tx)-related side effects (SE) among patients (pts) with early breast cancer (EBC)

• DOI: 10.1016/j.esmoop.2024.103331
• Publication Date: 2024-05-17T11:21:29Z
• Authors: A. Di Meglio; G. Catanuto; M. Zambon; A. Chan; A. Kassianos; C. Cloconi; S. Rohr; R. Steele; M. Coersmeyer; S. Ujupan; F.A. Peccatori

EBC care is multidisciplinary and should include comprehensive timely management of tx-related SE. We assessed patient-reported experiences preferences about information on SE received during care. An international multi-stakeholder expert group (oncology, surgery, nursing, pharmacy, psychology, patient advocacy, industry) was formed conducted a survey (by email phone follow-up) assessing comprehensiveness, timing, delivery modality Patients with that were primary (PTx) or endocrine therapy (ET) had discussed tx options health provider (HCP) eligible. Descriptive analyses performed. From June-August 2023, 608 respondents from Brazil (n=101), France (n=100), Germany Italy (n=106), Japan Spain (n=100) completed the survey: 58% <50 years old, 92% female, 14% been diagnosed ≥10 earlier, all ET. Fatigue most common PTx ET (47% 42%, respectively), 47% 51% pts reporting very high impact quality life (QOL). Among ET, respectively, 69% 71% reported receiving sufficient fatigue its management, 63% 65% before onset symptoms. Fewer patients urinary problems (8% 5%), however 67% 61%, symptoms QOL. Most would prefer HCP to be proactive in providing (74%), preventative strategies (73%), self-management programs (71%). Information direct interactions physician (70%) nurse (58%) deemed likely improve (vs printed materials, websites, support groups). This recommends leveraging pts' feedback deliver personalized, detailed, actionable their including for least prevalent ones. Co-creation tailored communication can enhance empowerment engagement, care, limit